Cantor Fitzgerald calls attention to Alnylam’s Amvuttra’s 30% royalty burden
Cantor Fitzgerald said that while the firm “congratulates” Alnylam Pharmaceuticals (ALNY) on last week’s Amvuttra approval, with the stock ...